Atomic map gives malaria drug new lease on life

March 13, 2017, Walter and Eliza Hall Institute
Dr. Brad Sleebs (left) and Dr. Wilson Wong from the Walter and Eliza Hall Institute have produced a precise atomic map of the frontline antimalarial drug mefloquine (pictured), showing how its structure could be tweaked to make it more effective in killing malaria parasites. Credit: Walter and Eliza Hall Institute of Medical Research

Researchers have for the first time mapped how one of the longest-serving malaria drugs works, opening the possibility of altering its structure to make it more effective and combat increasing malaria drug resistance.

The study produced a precise atomic map of the frontline antimalarial drug mefloquine, showing how its structure could be tweaked to make it more effective in killing parasites.

Dr Wilson Wong and Dr Brad Sleebs led the research at the Walter and Eliza Hall Institute, with Dr Jake Baum at Imperial College London, Dr Sjors Scheres from the Laboratory of Molecular Biology, Cambridge, and Dr Stuart Ralph at Melbourne's Bio21 Institute. The paper was published today in Nature Microbiology.

While drug treatments and preventative medicines for malaria are available, some have serious side effects and drug resistance means there is an urgent need for new treatments.

Many drugs that enter the market are known to kill harmful pathogens, but their exact mechanism for doing so is often unknown.

Dr Wong said it was the first time any team had identified one of the modes of action of mefloquine. "Mefloquine has been in use for more than 40 years, yet we did not understand how it was killing the parasite until now," he said.

The team used , which produces images of biological molecules in their natural state in unprecedented detail, to see exactly how and where the drug binds the malaria parasite. "We discovered that mefloquine attacks the ribosome - the molecular machinery that manufactures proteins required for malaria parasite survival," Dr Wong said.

Mefloquine has been associated with some serious side effects, including neurological symptoms. While mefloquine's attack on the ribosome is analysed in this study, the authors point out that the drug likely targets other parts of the parasite too, killing it through multiple modes of action.

Dr Wong said the detailed atomic map would enable future drug improvements. "We now know mefloquine binds to a hotspot of activity on the ribosome surface," he said. "However our map of the ribosome and drug-binding site showed the fit is not perfect. We were able to mimic this interaction with compounds that were able to block the protein machinery and kill the parasite more effectively."

Dr Sleebs said using this information to redesign the drug to be more targeted and better differentiate between malaria and human ribosomes would be the next step. "If we could create a drug that targets this particular mode of action, it could be more efficient and potentially more safe for treating malaria."

The malaria parasite ribosome with mefloquine (the drug) in pink. Credit: Wong et al., 2017

Dr Jake Baum from Imperial College London said improving the action of existing drugs was a cheaper, quicker way of getting new treatments to patients. "It takes a lot of resources to discover new drugs, but by tweaking the structure of existing drugs we can breathe new life into them, and potentially gain significant benefits with far fewer resources," Dr Baum said. "With growing resistance to frontline antimalarial drugs, it makes sense to improve secondary drugs that work imperfectly, rather than always reinvent the wheel."

Cryo-electron microscopy continues to be a revolutionary technique to investigate the mode of action of new and existing therapies, and could be applied to many other drugs to help improve their design, or design completely new drugs de novo. Seen in this light, drug design with a microscope is likely to become a powerful tool for discovery for many of our most deadly pathogens.

Explore further: New discovery could help turn antibiotic into antimalarial drug

More information: [52] Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis, Nature Microbiology, nature.com/articles/doi:10.1038/NMICROBIOL.2017.31

Related Stories

New hybrid drug plugs the hole in malaria drug resistance

April 11, 2016

A combination of artemisinin and another drug (artemisinin combination therapy, ACT) is currently the best malaria treatment recommended by the World Health Organization. In early 2015, artemisinin-resistant malaria was confirmed ...

First drug-resistant malaria parasite detected in Africa

February 22, 2017

For the first time in Africa, researchers said Wednesday they have detected a malaria parasite that is partially resistant to the top anti-malaria drug, artemisinin, raising concern about efforts to fight a disease that ...

Scientists exploit malaria's Achilles' heel

July 25, 2016

Malaria researchers at The Australian National University (ANU) have found one of the malaria parasite's best weapons against drug treatments turns out to be an Achilles' heel, which could be exploited to cure the deadly ...

Recommended for you

A decade on, smartphone-like software finally heads to space

March 20, 2019

Once a traditional satellite is launched into space, its physical hardware and computer software stay mostly immutable for the rest of its existence as it orbits the Earth, even as the technology it serves on the ground continues ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.